OTC birth control arrives amid the battle over reproductive rights
Opill will cost $19.99 a month. Democrats are pushing to make it cheaper.
Cheap, easy birth control is arriving in the United States. The country's first over-the-counter birth control pill "will soon become the most effective birth-control method available without a doctor's visit," said The Wall Street Journal. The pill — called Opill, available for $19.99 a month — is a "milestone that reproductive activists have pursued for decades." And it comes amid fierce political battles over reproductive rights in America.
One might ask why it took so long for OTC birth control to get here. America, after all, follows "more than 100 countries that permit the sale of contraceptive pills without a prescription," said Axios. Whatever the reason for the delay, it's clear that the end of Roe v. Wade in 2022 provided some urgency to the effort: The American College of Obstetricians and Gynecologists argued in recent years that easing access to the pill was "critical so that more people can control their reproductive fates."
The availability of birth control in the United States has traditionally "been dependent on access to health insurance and to a regular health care provider who could prescribe it," said the Center for American Progress, a liberal think tank. For many women, "use of and access to family planning services varies considerably." Opill's new availability removes some of those barriers, which "marks a pivotal moment in birth control access."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Is insurance coverage next?
While the price tag for Opill is relatively low, some lawmakers want to make it even cheaper for buyers. "Dozens" of congressional Democrats in October called on federal agencies "to ensure that private health insurance plans will fully cover the pill without a prescription," said CNN. And Sen. Patty Murray (D-Wash.) last year introduced the "Affordability is Access Act," which would put that requirement into law. Murray — along with Sens. Mazie Hirono (D-Hawaii), and Catherine Cortez Masto (D-N.V.) — this week renewed the call to pass the bill. "More needs to be done to make sure every American can access and afford the pill over the counter," the senators said in a joint statement.
That might be smart election-year politics for Democrats. Opposition to protections for birth control "may come back to haunt Republicans in November," The New York Times said. Recent polling shows that 80% of voters say that access to contraceptives is "deeply important," and that 72% had a "favorable view" of birth control. All but eight GOP members of the House opposed a 2022 bill to protect contraception. But nearly two-thirds of poll respondents said that made them less likely to vote Republican this year — a "political crisis" for the GOP.
The recent Alabama Supreme Court ruling — affirming personhood for frozen embryos used in vitro fertilization — has only intensified the crisis. Now Democrats are "seeking to make the connection between Alabama's IVF decision and birth control restrictions," said The Guardian. Republicans are trying to find a middle ground on the issue, expressing support for IVF without alienating their anti-abortion supporters. It's a tricky balancing act. "They can't win without anti-abortion base voters," said one observer.
'Little public opposition'
Given those fights, it's notable that federal approval for Opill "faced very little public opposition from conservative groups," said The New York Times. While some Catholic organizations pushed back against the pill, other groups that are "often critical of measures that increase access to abortion, emergency contraception and sex education" stayed silent on the topic. That could prove a rare break from political battles this year. "The issue of reproductive rights was always going to loom large in the 2024 U.S. elections," said Voice of America.
In the meantime, CNN said, consumers should start to see the pills on store shelves in the coming weeks. Under the Affordable Care Act, most health insurance plans will cover the cost — and Perrigo, the company behind Opill, said it will soon announce a "cost assistance" program for low-income people. The idea, said one company official, is to "ensure both affordability and availability on shelf."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Joel Mathis is a writer with 30 years of newspaper and online journalism experience. His work also regularly appears in National Geographic and The Kansas City Star. His awards include best online commentary at the Online News Association and (twice) at the City and Regional Magazine Association.
-
Best of frenemies: the famous faces back-pedalling and grovelling to win round Donald Trump
The Explainer Politicians who previously criticised the president-elect are in an awkward position
By Chas Newkey-Burden, The Week UK Published
-
Quiz of The Week: 9 - 15 November
Have you been paying attention to The Week's news?
By The Week Staff Published
-
The Week Unwrapped: Will China's 'robot wolves' change wars?
Podcast Plus, why are Britain's birds in decline? And are sleeper trains making a comeback?
By The Week Staff Published
-
The dark side of the contraceptive coil
Under the Radar Study linking hormonal IUD to increased breast cancer risk adds to growing concerns about whether the benefits of the coil outweigh the risks
By Harriet Marsden, The Week UK Published
-
Pink cocaine: the new drug cocktail responsible for an increasing number of deaths
In the Spotlight The substance has been linked to the death of Liam Payne and named in a lawsuit against Sean 'Diddy' Combs
By Justin Klawans, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Why scurvy is on the rise
The Explainer Cost of living and poor dietary choices fuelling a potential resurgence of condition associated with the Age of Sail
By Richard Windsor, The Week UK Published
-
Cameroon bans reports on health of missing President Biya
Under the Radar Biya, 91, hasn't been seen in public in weeks, fuelling widespread speculation that he might be dead
By Harriet Marsden, The Week UK Published
-
What went wrong at CVS?
Today's Big Question Pharmacy chains are in crisis
By Joel Mathis, The Week US Published
-
The 'game-changing' treatment for schizophrenia
The Explainer US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects
By Harriet Marsden, The Week UK Published
-
The audio industry is working to tackle hearing aid stigma
The Explainer Only 1 in 5 people who could benefit from hearing aids use them, according to the Hearing Loss Association of America
By Justin Klawans, The Week US Published